 |
answer text |
<p>The decision not to procure Evusheld at this time for prevention through emergency
routes is based on independent clinical advice by the multi-agency RAPID C-19 and
a national expert policy working group. The decision is based on a range of evidence,
including clinical trial data, in vitro analysis and emerging observational studies.
RAPID C-19 monitors activity in clinical trials for emerging evidence and where treatments
are proven to be clinically effective, enables access for National Health Service
patients. The Chief Medical Officer for England is content that the correct process
for providing clinical advice has been followed and it should now be referred to the
National Institute for Health and Care Excellence for further evaluation. The Antivirals
and Therapeutics Taskforce has published this analysis of evidence, which is available
at the following link:</p><p><a href="https://www.gov.uk/government/publications/rapid-c-19-oversight-group-report-to-chief-medical-officer-review-of-evusheld"
target="_blank">https://www.gov.uk/government/publications/rapid-c-19-oversight-group-report-to-chief-medical-officer-review-of-evusheld</a></p><p>A
letter was issued to patient groups on 5 September on the evidence and expert analysis
for the decision, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups"
target="_blank">https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups</a></p>
|
|
